Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.53 |
| ▸ | AXL | P30530 | 4/20 | 0.53 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.53 |
| ▸ | KIT | P10721 | 2/20 | 0.53 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.53 |
| ▸ | MET | P08581 | 12/20 | 0.51 |
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | RET | P07949 | 1/20 | 0.47 |
| ▸ | IGF1R | P08069 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | MST1R | Q04912 | 1/20 | 0.47 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | TEK | Q02763 | 1/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20022514 | 0.93 | KDR (0.51) | KDRAXLPDGFRAKITFGFR2 | |
| SCHEMBL20022522 | 0.90 | KDR (0.55) | KDRAXLPDGFRAKITFGFR2 | |
| SCHEMBL20022511 | 0.86 | KDR (0.52) | KDRAXLPDGFRAKITFGFR2 | |
| SCHEMBL20022518 | 0.85 | KDR (0.53) | KDRAXLPDGFRAKITFGFR2 | |
| SCHEMBL20022516 | 0.82 | KDR (0.55) | KDRAXLPDGFRAKITFGFR2 | |
| SCHEMBL20022528 | 0.81 | KDR (0.53) | KDRAXLPDGFRAKITFGFR2 | |
| SCHEMBL20022521 | 0.81 | MET (0.54) | KDRAXLPDGFRAKITFGFR2 | |
| SCHEMBL20022512 | 0.80 | MET (0.53) | KDRAXLPDGFRAKITFGFR2 | |
| SCHEMBL20022515 | 0.78 | KDR (0.51) | KDRAXLPDGFRAKITFGFR2 | |
| SCHEMBL20022517 | 0.77 | KDR (0.53) | KDRAXLPDGFRAKITFGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10934274-B2 | Quinoline derivatives as TAM RTK inhibitors | QURIENT CO., LTD. (KR) | 2021-03-02 | — | — | US | disclosed |
| US-20180093968-A1 | QUINOLINE DERIVATIVES AS TAM RTK INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2018-04-05 | — | — | US | disclosed |
| US-20180093968-A1 | QUINOLINE DERIVATIVES AS TAM RTK INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934274-B2 | Quinoline derivatives as TAM RTK inhibitors | TYRO3, MERTK, AXL | KDR 19/4885AXL 3/4885PDGFRA 111/4885 |
| US-20180093968-A1 | QUINOLINE DERIVATIVES AS TAM RTK INHIBITORS | TYRO3, MERTK, AXL | KDR 19/4885AXL 3/4885PDGFRA 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.